CoNCERT Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
CoNCERT Pharmaceuticals' latest press release shows exciting potential for CTP-543 to be a best-in-class treatment for alopecia areata.
What Treatments are Available for Alopecia Areata?
Dermatologist Dr. Jeffrey Donovan provides an overview of the treatments available for alopecia areata in a recent blog post. Link to article is within.
What is the Alopecia Areata Scale?
Clinical experts have developed a tool called the Alopecia Areata Scale to assess the severity of alopecia areata. This tool, unlike past methods accounts for more than scalp hair loss.
COVID-19 Vaccines and Alopecia Areata: What is the Relationship?
Learn how the COVID-19 vaccine works and the relationship between mRNA vaccines and alopecia areata.
What is Patient Engagement?
You or a loved one can be involved in Alopecia Areata research. Learn more about patient engagement in research and why it's important.
Concert Pharmaceuticals begins THRIVE-AA2 phase 3 clinical trial for JAK inhibitors (CTP-543)
CANAAF is thrilled to share that Concert Pharmaceuticals has announced the launching of THRIVE-AA2, the second planned Phase 3 clinical trial to evaluate the efficacy and safety of CTP-543, an oral Janus kinase (JAK) inhibitor, in adult patients with moderate to severe alopecia areata. Concert expects to report the preliminary results of
Watch Dr. Donovan’s update from 2020 and learn about recent advancements in alopecia research.